OverviewSuggest Edit

Biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor-associated DNA , both in Circulating Tumor Cells and in plasma (cell-free circulating tumor DNA). The Company's mission is to improve outcomes for cancer patients by advancing oncology diagnostics. Biocept utilizes patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. Additionally, the Company offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. Biocept's strategic focus is to promote its unique technology (CEE, cell enrichment and extraction) and family of laboratory tests (OncoCEE) to the Oncology Community. 

The CEE system has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. Examples of these rare cells are circulating tumor cells in patients with early-stage, metastatic or recurrent cancers. Biocept provides products and services to detect and analyze these rare cells in order to provide information that physicians can use to make treatment decisions. The Company employs its unique laboratory tests through an offering of services to medical/surgical oncologists, pathologists, hospitals, cancer centers, universities, and pharmaceutical/clinical researchers.

TypePublic
Founded1993
HQSan Diego, US
Websitebiocept.com

Latest Updates

Employees (est.) (Dec 2018)87(-8%)
Job Openings2
Revenue (FY, 2019)$5.5 M(+71%)
Share Price (Sept 2020)$4.5 (+3%)
Cybersecurity ratingAMore

Key People/Management at Biocept

David F. Hale

David F. Hale

Chairman of the Board
Michael W. Brown

Michael W. Brown

General Counsel, Compliance and Privacy Officer
Michael Terry

Michael Terry

Senior Vice President, Corporate Development
Michael W. Nall

Michael W. Nall

President and Chief Executive Officer
Deirdre Goehler

Deirdre Goehler

Senior Director of Managed Care Strategies
Marsha A. Chandler

Marsha A. Chandler

Director
Show more

Biocept Office Locations

Biocept has an office in San Diego
San Diego, US (HQ)
5810 Nancy Ridge Dr
Show all (1)

Biocept Financials and Metrics

Biocept Revenue

Biocept's revenue was reported to be $5.53 m in FY, 2019
USD

Revenue (Q2, 2020)

917.5k

Gross profit (Q2, 2020)

(1.6m)

Gross profit margin (Q2, 2020), %

(174.4%)

Net income (Q2, 2020)

(6.5m)

EBIT (Q2, 2020)

(6.4m)

Market capitalization (18-Sept-2020)

60.1m

Closing stock price (18-Sept-2020)

4.5

Cash (30-Jun-2020)

24.1m

EV

38.0m
Biocept's current market capitalization is $60.1 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

5.1m3.3m5.5m

Revenue growth, %

(36%)

Cost of goods sold

6.9m9.3m10.1m11.0m

Gross profit

(4.3m)(6.8m)(5.4m)
Quarterly
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

4.6m2.1m3.4m9.3m

Accounts Receivable

129.0k1.2m1.6m3.5m

Prepaid Expenses

296.1k

Inventories

484.6k498.7k587.2k768.0k
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

14.0m10.0m5.9m9.3m2.6m9.0m14.8m12.6m6.5m21.5m24.1m

Accounts Receivable

834.9k994.7k1.1m1.3m1.4m1.5m1.9m2.2m2.9m3.4m3.2m

Prepaid Expenses

586.3k497.1k429.1k852.1k

Inventories

525.5k631.2k775.1k491.0k537.0k581.5k577.3k605.5k687.2k918.7k973.7k
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(18.4m)(21.6m)(24.6m)(25.1m)

Depreciation and Amortization

322.0k575.7k800.9k931.7k

Inventories

494.7k100.9k(50.0k)(194.9k)

Accounts Payable

332.7k349.9k601.9k14.8k
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(6.4m)(12.5m)(18.6m)(5.9m)(13.7m)(19.4m)(8.3m)(14.8m)

Depreciation and Amortization

179.8k357.2k580.4k222.1k451.0k691.2k242.8k477.4k

Inventories

412.9k22.4k30.4k9.7k9.4k(27.1k)(120.2k)(176.0k)(259.9k)

Accounts Payable

1.4m1.8m1.6m204.2k435.7k413.7k152.6k(71.7k)(198.4k)412.9k(4.9k)
USDFY, 2016

Financial Leverage

11.5 x
Show all financial metrics

Biocept Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Biocept Online and Social Media Presence

Embed Graph

Biocept News and Updates

Biocept to Present at the Proactive One2One Virtual Investor Forum on August 25

SAN DIEGO, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that President and CEO Michael Nall will present at t…

Thinking about buying stock in Immatics NV, Biocept Inc, LMP Automotive, Unity Biotechnology, or Barrick Gold Corp?

NEW YORK, Aug. 18, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IMTX, BIOC, LMPX, UBX, and GOLD. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in SINTX Technologies, China Automotive Systems, Athersys Inc, Theratechnologies, or Biocept Inc?

NEW YORK, June 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SINT, CAAS, ATHX, THTX, and BIOC. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Biocept, TOP Ships, Aclaris Therapeutics, Seanergy Maritime, or InnerWorkings?

NEW YORK, June 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIOC, TOPS, ACRS, SHIP, and INWK. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in TOP Ships, Hertz, Biocept, Edesa Biotech, or Adamis Pharmaceuticals?

NEW YORK, June 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TOPS, HTZ, BIOC, EDSA, and ADMP. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Biocept, Celsion Corp, Tilray, Altimmune, or Ford?

NEW YORK, May 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIOC, CLSN, TLRY, ALT, and F. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

Biocept Frequently Asked Questions

  • When was Biocept founded?

    Biocept was founded in 1993.

  • Who are Biocept key executives?

    Biocept's key executives are David F. Hale, Michael W. Brown and Michael Terry.

  • How many employees does Biocept have?

    Biocept has 87 employees.

  • What is Biocept revenue?

    Latest Biocept annual revenue is $5.5 m.

  • What is Biocept revenue per employee?

    Latest Biocept revenue per employee is $63.5 k.

  • Who are Biocept competitors?

    Competitors of Biocept include Evox Therapeutics, Cancer Targeted Technology and NeoProteomics.

  • Where is Biocept headquarters?

    Biocept headquarters is located at 5810 Nancy Ridge Dr, San Diego.

  • Where are Biocept offices?

    Biocept has an office in San Diego.

  • How many offices does Biocept have?

    Biocept has 1 office.